Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Apr 2:7:57.
doi: 10.1186/1748-717X-7-57.

Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

Alexandra D Jensen  1 , Jürgen Krauss, Karin Potthoff, Christian Simon, Anna V Nikoghosyan, Karen Lossner, Jürgen Debus, Marc W Münter
Affiliations
Clinical Trial

Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial

Alexandra D Jensen et al. Radiat Oncol. .

Abstract

Purpose: To evaluate efficacy and toxicity clinical in the intensified treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN) with the combination of chemotherapy, the EGFR antibody cetuximab, and intensity-modulated radiation therapy (IMRT) in a concomitant boost concept.

Methods: REACH is a prospective, bi-centric phase II trial of carboplatin/5-FU and cetuximab weekly combined with IMRT. Primary endpoint is locoregional control, secondary endpoints include acute radiation effects and adverse events. Evaluation of disease response is carried out according to the Response Evaluation Criteria in Solid Tumors (RECIST); toxicity is assessed using NCI CTC v 3.0.

Results: Treatment was tolerated moderately well, acneiforme erythema occurred in 74.1% (grade II/III), mucositis grade III in 28.6%, and radiation dermatitis grade III in 14.3%. Higher-grade side-effects resolved quickly until the first follow-up post treatment. Objective response rates were promising with 28.6% CR at first follow-up and 92.9% thereafter.

Conclusion: The combination of standard carboplatin/5-FU and cetuximab is feasible and results in promising objective response rates. The use of an IMRT concomitant boost is practicable in a routine clinical setting resulting in only moderate overall toxicity of the regimen.

Trial registration number: ISRCTN87356938.

PubMed Disclaimer

Figures

Figure 1
Figure 1
50 y old patient with oro-/hypopharyngeal carcinoma; planning MRI.
Figure 2
Figure 2
50 y old patient with oro-/hypopharyngeal carcinoma; planning CT.
Figure 3
Figure 3
50 y old patient with oro-/hypopharyngeal carcinoma; complete remission 6 weeks post completion of therapy.
Figure 4
Figure 4
50 y old patient with oro-/hypopharyngeal carcinoma; complete remission 4 months post completion of therapy.
Figure 5
Figure 5
Overall progression-free survival (PFS) (n = 14 pts). PFS at 1 year: 84.4%; PFS at 2 years 63.3%.
See this image and copyright information in PMC

References

    1. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949–955. - PubMed
    1. Pignon JP, le Maitre A, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69:S112–114. - PubMed
    1. Pignon JP, le Maitre A, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14. doi: 10.1016/j.radonc.2009.04.014. - DOI - PubMed
    1. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–854. doi: 10.1016/S0140-6736(06)69121-6. - DOI - PubMed
    1. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28. doi: 10.1186/1471-2407-6-28. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data